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treatment, shortening “patient paths” and establishing centers of wound treat-
ment would be recommended in Hungary.
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Objectives: In Italy, standard treatment care of patients with neovascular (“wet”) 
age-related macular degeneration (wAMD) is currently performed with ranibi-
zumab (RBZ) on as-needed basis (PRN). The objective of this study was to assess 
the cost-effectiveness of intravitreal aflibercept (IVT-AFL), administered every 
other month vs. RBZ PRN treatment, in the Italian treatment setting. MethOds: 
A Markov model was built to compare IVT-AFL compared to RBZ PRN in wAMD. 
Health states were based on visual acuity in the better-seeing eye. In the model, 
patients may remain in the same status (same visual acuity), progress to another 
status or die. A proportion of patients may also discontinue treatment monthly 
or upon becoming blind. Parameters were estimated from two randomized phase 
III studies VIEW 1/VIEW 2, published literature or expert opinions. Analyses were 
performed from the Italian Healthcare perspective, using a 20-year time hori-
zon (starting age was 77 years). The simulation model calculated costs (drug, 
administration, monitoring, vision impairment and adverse events), quality-
adjusted life-years (QALYs) and incremental cost-effectiveness ratios (ICERs), all 
discounted at 3% annually. Deterministic and probabilistic sensitivity analyses 
(SA) were performed to test the robustness of the results. Results: IVT-AFL 
costs 30,852€ compared with 33,636€ for RBZ PRN; QALYs totaled 2.651 for IVT-
AFL and 2.638 for RBZ-PRN respectively. IVT-AFL is associated with less cost and 
more QALYs gained than RBZ-PRN and hence dominates RBZ PRN. Deterministic 
SA showed that the results were most sensitive to changes in efficacy and time 
horizon, while probabilistic SA showed that 90% of the iterations fell within the 
cost-effectiveness threshold deemed acceptable for Italian Payers (for example 
€ 40,000). cOnclusiOns: Results indicate that, within the Italian treatment set-
ting, attainment of maximal visual gains via IVT-AFL is cost-saving that means less 
costly and more effective (more QALYs gained) compared to RBZ PRN.
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Objectives: To evaluate the cost-effectiveness of ranibizumab compared with 
verteporfin photodynamic therapy (vPDT) for the treatment of patients with visual 
impairment due to choroidal neovascularization (CNV) secondary to pathologic 
myopia (PM). MethOds: A Markov model with a 3-month cycle length and health 
states defined by best-corrected visual acuity (BCVA) was developed from the UK 
health care provider perspective. A lifetime time horizon was applied, and future 
costs and outcomes were discounted at 3.5%/year. Baseline characteristics were 
derived from the phase 3 RADIANCE study; year 1 health state transitions and 
treatment frequency were based on the RADIANCE study and a vPDT study (VIP). 
Treatment was given beyond year 2 only in cases of mCNV recurrence (6%/year). 
Existing literature was used to estimate BCVA transitions beyond 12 months. Health 
states were based on the visual acuity of the study eye, which could be each patient’s 
better-seeing eye (BSE) or worse-seeing eye (WSE). BSE utility values came from a 
published source. Results: The mean lifetime cost of ranibizumab treatment was 
slightly lower than the cost of vPDT. Ranibizumab was associated with higher life-
time quality-adjusted life-years (QALYs) than vPDT (relative gain of 0.43), reflecting 
higher utility values and reduced mortality with ranibizumab. Ranibizumab there-
fore dominated vPDT. Ranibizumab had a 100% probability of being cost-effective 
compared with vPDT at a willingness-to-pay threshold of £20 000 per QALY. The 
model was sensitive to the number of ranibizumab injections in year 1. Ranibizumab 
remained cost-effective even when the mean number of ranibizumab injections 
increased from 3.5 (base case) to 12 and the mean number of vPDT treatments 
remained constant (3.4) in year 1. cOnclusiOns: Ranibizumab is less costly and 
is associated with a gain in QALYs relative to vPDT for the treatment of patients 
with visual impairment due to CNV secondary to PM in the UK.
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Objectives: To evaluate the cost-effectiveness of biologic treatments for moderate 
to severe psoriasis in the UK. MethOds: A decision model similar to those utilized 
in NICE appraisals TA103, TA134, TA146, and TA180 was constructed consisting of 
2 distinct periods, the trial and treatment periods. Clinical efficacy was estimated 
during the trial period based on the relative probabilities of achieving Psoriasis Area 
and Severity Index (PASI) response (50/75/90) obtained via a network meta-analysis 
of 15 randomized controlled trials of adalimumab, etanercept, infliximab, and usteki-
numab. Weight-based dosing was calculated for infliximab and ustekinumab to reflect 
licensed use. Only patients who achieved PASI 75 response in the trial period contin-
ued into the treatment period. Treatment benefits were determined by the relation-
ship between predicted PASI response and the EQ-5D health utility measure. Costs 
(2011 British pounds) were assessed from a UK National Health Services perspec-
tive and included drug acquisition, administration, monitoring and hospitalization 
coverage ≥ 6 months before (baseline period) and ≥ 12 months post-index date were 
selected from the MarketScan Commercial and Medicare Claims database (2005-2009). 
The index date was defined as the last day of conventional systemic or biologic drug 
coverage. Discontinuation was defined as no systemic or no biologic treatment for ≥ 
12 consecutive months from the last day of systemic or biologic prescription coverage. 
Patients were classified as having discontinued from a biologic if there was evidence 
of biologic drug use during the baseline period; otherwise they were defined as hav-
ing discontinued from non-biologic systemic therapy. Twelve-month average costs 
following discontinuation were reported. Results: A total of 4,720 psoriasis patients 
met the selection criteria; 67.4% discontinued from non-biologic systemic therapy 
and 32.6% from biologic therapy. Over the 12-month period following discontinu-
ation, total costs were $10,577 (SD: 19,910) and $9,001 (SD: 16,401) for biologic and 
non-biologic discontinuers, respectively (p= 0.004). Outpatient and medication costs 
were significantly higher for the biologic discontinuers compared to the non-biologic 
discontinuers ($5,283 vs. $4,449, p= 0.003, and $2,738 vs. $2,470, p= 0.022, respec-
tively). There was no statistically significant difference in hospital/ER costs ($2,556 
vs. $2,083, p= 0.214, respectively). Outpatient costs accounted for approximately 50% 
of total costs for both cohorts. cOnclusiOns: This study suggests that outpatient 
costs account for a substantial proportion of health care costs in psoriasis patients 
who discontinued from systemic or biologic therapy. Patients who had discontinued 
from biologic therapy incurred significantly higher outpatient and medication costs 
compared to patients who had discontinued from conventional systemic therapy.
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Objectives: Chronic leg ulcers without healing tendency present a serious public 
health and socio-economic issue. Rationally combinig causal and conservative treat-
ments with innovative methods, it would be beneficial to improve the effectivity of 
wound treatment, thus reducing its financial impacts. The aim of study was to inves-
tigate the cost of conservative treatment and an innovative Negative Pressure Wound 
Therapy (NPWT). MethOds: The authors present cases of dermatological patients 
with severe, chronic leg ulcers of various etiologies resistant to conservative therapy 
(Patients-1: fasciitis necrotisans; Patients-2: ulcer associated with chronic venous 
insufficiency; Patients-3: pyoderma gangrenosum), thus comparing the costs of con-
servative treatment (social insurance subsidies on bandages) and NPWT (not financed 
by social insurance) in each patient. Furthermore, the authors compare costs of NPWT 
cases with other cases (Patient-4: fasciitis necrotisans; Patient-5: ulcer associated with 
chronic venous insufficiency; Patient-6: ulcer associated with rheumatoid arthritis), 
in which no NPWT was applied thus far due to financial reasons. (1USD$= 225 HUF, 
Hungarian Forint). Results: Social insurance subsidies on bandages/patient (USD) 
in treatment period: Patient-1.: $1324; Patient-2.: $15495; Patient-3.: $412; Patient-4.: 
$11376; Patient-5.: $10557; Patient-6.: $7306. Cost of NPWT/patient and proportion of 
social insurance subsidies on bandages/patient: Patient 1.: $1405 (106%); Patient 2.: 
$667 (4.3%), Patient 3.: $778 (188.9%). The cost of NPWT is relatively high, however, 
NWPT-treated leg ulcers have healed compared to cases receiving conservative treat-
ment, which can be attributed to NPWT stimulating wound healing. cOnclusiOns: 
Treatment of the disease resulting leg ulcer – causal therapy combined with NPWT – is 
beneficial in wound healing, reducing high costs of wound treament, shortening the 
time of wound healing, improving the patient’s quality of life. Application of NPWT 
in specialized centers of wound treatment and financing by social insurance would 
be recommended for cases not responding to conservative treatment in Hungary.
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Objectives: Incidence of chronic leg ulcers without healing tendency exceeds 1% 
among adults and 3-5% among people over 65 years. The burden of diseases caused 
by wounds without healing tendencies can only be estimated. Complications of 
chronic wounds are severe, life-threatening. Total social insurance subsidies on 
bandages in Hungary is 22-26 million USD/year. Using case studies the authors 
emphasize the importance of (differential) diagnosis, mistakes of wound treat-
ment affecting healing and increasing costs of treatment, in contrast to therapy 
costs. MethOds: The authors present leg ulcer cases of various etiologies referred 
to the dermatological clinic, seeking mistakes of wound treatment, examining 
social insurance subsidies on bandages, based on bandage prescriptions. Patients 
1-4.: Ulcus cruris due to chronic venous insufficiency; Patient 5.: Leg ulcer caused 
by lymphoedema; Patients 6-8.: Ulcerous malignancies treated as leg ulcers; 
Patient 9.: Ulcus cruris+myeloproliferative disease; Patient 10.: Bilateral leg ulcers 
resulting from cardial decompensation and diabetes mellitus. (1USD$= 225 HUF, 
Hungarian Forint). Results: Social insurance subsidies (USD) on bandages per 
patients and mistakes in wound therapy: Patient 1.: $1857; Patient 2.: $1639; Patient 
3.: $1787; Patient 4.: $53329, lack of compression therapy and lymphatic massage; 
Patient 5.: $12.567, lack of lymphatic massage; Patient 6.: $213; Patient 7.: $294; 
Patient 8.: $2143, lack of correct diagnosis; Patient 9.: $2993, no treatment of con-
comitant hematologic disease; Patient 10.: insufficient therapy of co-morbidities: 
diabetes, obesity, cardial decompensation. cOnclusiOns: Modern treatment of 
leg ulcers mainly aims at determining primary causes, treating diseases causing 
wound healing disorders, namely causal therapy. Inefficient wound treatment 
is costly, application of modern bandages without principles, not treating co-
morbidities and treating on inadequete levels cause financial problems to both the 
patient and the social insurance. Introducing professional guidelines for wound 
A506  VA L U E  I N  H E A LT H  1 6  ( 2 0 1 3 )  A 3 2 3 – A 6 3 6  
was adapted to the Portuguese setting to evaluate the cost-effectiveness (CEA) of 
linezolid vs.vancomycin in MRSA cSSTI. MethOds: Published Bayesian evidence 
synthesis results were used to populate efficacy parameters of the model. Resource 
utilization and MRSA prevalence rates were obtained through an expert panel of 
Portuguese clinicians and costs from published sources were applied to resource 
units. Analyses were done from the Portuguese NHS perspective. Both univariate 
and probabilistic sensitivity analyses were performed to test the robustness of model 
results. Results: Average cost per patient for linezolid and vancomycin treatments 
were 15,195€ and 17,345€ respectively. Average effectiveness gained with linezolid 
treatment was 0.002QALYs. Average saving obtained with linezolid treatment was 
2150€ per patient. cOnclusiOns: Linezolid is a dominant strategy compared to 
vancomycin: less costly and more effective. Compared to vancomycin, linezolid is 
expected to result in lower total costs that offset its higher acquisition cost in cSSTI 
in Portugal.
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Objectives: To assess the cost-effectiveness of ranibizumab compared to verteporfin 
in photodynamic therapy (vPDT) for the treatment of myopic choroidal neovasculari-
zation (mCNV) from the Canadian health care and societal perspectives. MethOds: 
A Markov model was used to follow a cohort of 55-year old patients with mCNV over 
a lifetime horizon. The model included 8 health states based on best corrected visual 
acuity (BCVA) and an absorbing death state. Patients were allowed to remain in their 
current health state, or transition to other health states or death every 3 months. 
Results from the RADIANCE trial were used to inform the first year transitions for 
patients receiving ranibizumab, and the first 3 months for those on vPDT. The VIP 
trial was used to estimate month 4-12 transitions for vPDT. Patients transitioned 
according to natural progression from year 2 onwards. Health state utilities were 
derived from a Canadian utility study and published sources. Resource use and costs 
were collected from clinical trials, published literature, expert opinion, and standard 
Canadian sources. Results: From the health care perspective, patients receiving 
ranibizumab for mCNV incurred less health care costs compared to those on vPDT 
(cost savings of $3,939). This was achieved while accruing an additional 0.07 life years 
(LYs) and 0.37 quality-adjusted life years (QALYs). Thus ranibizumab dominated vPDT. 
Similar findings were observed from the societal perspective (cost saving of $14,217). 
The average BCVA score remained consistently higher with ranibizumab compared to 
vPDT over the entire time horizon. cOnclusiOns: From a cost-effectiveness stand-
point, ranibizumab dominated vPDT in the treatment of mCNV, from both Canadian 
health care and societal perspectives. Patients on ranibizumab realized more QALYs 
and LYs at a lower cost compared to vPDT.
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Objectives: Monthly dosing with ranibizumab (RBZ) is needed to achieve maxi-
mal sustained visual gains in patients with neovascular (“wet”) age-related macular 
degeneration (wAMD). In Sweden dosing is on an as-needed (PRN) basis, resulting in 
suboptimal efficacy. Intravitreal aflibercept dosed every 2 months (IVT-AFL) demon-
strated clinically equivalent efficacy compared to RBZ monthly dosing (RBZ Q4) in a 
randomized clinical trial setting. We assessed the cost-effectiveness of IVT-AFL vs. 
RBZ Q4 and RBZ PRN real-life data, in a Swedish setting. MethOds: A Markov model 
compared wAMD treatment over two years with either IVT-AFL, RBZ Q4 or real-life 
RBZ PRN. Health states were based on visual acuity in the better-seeing eye; a propor-
tion discontinued treatment monthly or upon visual acuity < 20/400. Parameters were 
estimated from trial data, published literature, or expert opinion. Analyses were per-
formed from a societal perspective with a lifetime horizon (starting age 77 years). The 
model calculated costs (drug, administration, monitoring, vision impairment, adverse 
events, caregiver), quality-adjusted life-years (QALYs), and incremental cost-effec-
tiveness ratios (ICERs), all discounted 3% annually. Deterministic and probabilistic 
sensitivity analyses were performed. Results: IVT-AFL cost 578,400 SEK, compared 
with 686,600 SEK for RBZ Q4 and 565,700 SEK for real-life RBZ PRN; QALYs totaled 4.58 
for IVT-AFL, 4.59 for RBZ Q4, and 4.43 for real-life RBZ PRN. Compared with real-life 
RBZ PRN, IVT-AFL cost 80,000 SEK/QALY gained. RBZ Q4 cost over 20 million SEK/
QALY gained, compared with IVT-AFL Q8. The model was most sensitive to IVT-AFL 
efficacy and patient age. IVT-AFL had a 42% probability of dominating RBZ Q4 and a 
100% probability of being cost-effective vs. RBZ PRN, at an assumed willingness-to-pay 
threshold of 500,000 SEK. cOnclusiOns: Results suggest that, in Sweden, attainment 
of maximal visual gains via IVT-AFL is cost-effective compared with real-life RBZ PRN 
dosing. RBZ Q4 is not cost-effective relative to IVT-AFL.
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Objectives: To evaluate the cost-effectiveness of bimatoprost 0.03%/timolol 0.05% 
(BTFC) preservative-free (PF) fixed combination compared with dorzolamide/timolol 
costs. Drug acquisition cost for ustekinumab reflected the manufacturers’ UK Patient 
Access Scheme. Incremental cost-effectiveness ratios (ICERs) were calculated and 
treatments were ranked relative to supportive care. One-way sensitivity analyses, 
using alternative plausible values for key parameters, explored uncertainty in the 
results. Results: Infliximab provided the most additional quality-adjusted life-years 
(QALYs) vs. supportive care (0.186) followed by ustekinumab (0.174) and adalimumab 
(0.169). In the base case, adalimumab was the most cost-effective biologic (£19,082/
QALY vs. supportive care), followed by ustekinumab (£20,964/QALY), etanercept 25 mg 
BIW (£26,580/QALY), etanercept 50 mg BIW during the trial period followed by 25mg 
BIW (£28,719 per QALY), and infliximab (£46,844 per QALY). ICERs for ustekinumab 
and infliximab compared with adalimumab were £87,625 and £332,015, respectively. 
Adalimumab remained the most cost-effective in the majority of the sensitivity analy-
ses. cOnclusiOns: In this decision-model analysis, adalimumab was the most cost-
effective biologic treatment for moderate to severe psoriasis in the UK.
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Objectives: Ingenol mebutate gel is a recently developed, topical, 2 or 3 days patient-
administered AK therapy. The objective was to compare the cost-effectiveness of ingenol 
mebutate gel with diclofenac gel and other available therapies for the first-line treat-
ment of AK in adult patients, from the perspective of the National Health Service (NHS) 
in Scotland. MethOds: A cost-utility analysis was conducted using a decision tree 
approach to calculate the costs and benefits of different treatment strategies for AK over 
a 12-month time horizon. Data on the relative efficacy of treatment was derived from a 
systematic review of RCTs and a subsequent mixed-treatment comparison (MTC). Utility 
scores and resource use data were obtained from published sources. Due to the uncer-
tainty surrounding the impact of AEs on HRQoL and costs, AEs were modelled in a sce-
nario analysis. Results: In the primary comparison, ingenol mebutate 150 mcg/g gel and 
500 mcg/g gel were associated with ICERs of £44 and £114 per QALY gained, respectively 
compared with diclofenac (3%) for 8 weeks and £36 and £74, respectively compared with 
diclofenac (3%) for 12 weeks. In the secondary comparisons, ingenol mebutate 150 mcg/g 
gel and 500 mcg/g gel were associated with ICERs of £47 and £134, respectively compared 
with 5-FU/salicylic acid (0.5%/10%) cutaneous solution and dominated cryotherapy (i.e. 
were cheaper and more effective). Ingenol mebutate 150 mcg/g gel and 500 mcg/g gel were 
cheaper and less effective than 5-FU (5%) cream. Ingenol mebutate 150 mcg/g gel, but not 
ingenol mebutate 500 mcg/g gel, was cost-effective assuming a decision making will-
ingness-to-pay threshold of £20,000/QALY (for one additional QALY gained, there would 
be an incremental cost of £26,525 incurred for 5-FU (5%) cream vs ingenol mebu-
tate gel). cOnclusiOns: Ingenol mebutate gel is a fast-acting, convenient 
and, relative to most comparators, cost-effective therapy for the first-line treatment 
of AK.
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Objectives: To determine if providing high dose anti-oxidant vitamins + Zinc 
treatment to intermediate Age Related Macular Degeneration (AMD) patients 
aged 40-79 years from Singapore is cost effective in preventing progression to Wet 
AMD. MethOds: We estimated the number of AMD patients aged 40 to 79 years 
(Category 3 and 4) in the Singaporean resident population. This hypothetical cohort 
was followed for 5 calendar years to determine the number of patients who would 
progress to wet AMD given the following four treatment scenarios: a) Vitamins 
+Zn followed by Ranibizumab (as needed) for wet AMD; b) Placebo followed by 
Ranibizumab (as needed) for wet AMD; c) Vitamins + Zn followed by Bevacizumab 
(monthly) for wet AMD; and d) Placebo followed by Bevacizumab (monthly) for wet 
AMD. Costs were estimated for the above scenarios from the providers’ perspective 
and cost effectiveness was measured by cost per disability adjusted life year (DALY) 
averted with a disability weight of 0.22 for wet AMD. Crude annual mortality rate 
was incorporated into the model. Results: Over 5400 patients could be prevented 
from progressing to Wet AMD cumulatively over five years if preventive anti-oxidant 
vitamins +Zn treatment were prescribed. Vitamins + Zn followed by ranibizumab 
(as needed) or bevacizumab (monthly) was cost effective compared to placebo fol-
lowed by either drug (cost per DALY averted: $1885.8 - well within the threshold 
suggesting it is cost effective). However, bevacizumab (monthly 1 injection) alone 
was cost effective. Cost savings as a result of prescribing anti-oxidant vitamins +Zn 
were $ 46.7M for ranibizumab arm over 5 years. cOnclusiOns: Prophylactic treat-
ment with high dose anti-oxidant vitamins + Zn for intermediate AMD patients, 
followed by ranibizumab for patients who progressed to wet AMD was found to be 
cost-effective. These findings have implications for intermediate AMD screening, 
treatment and health care planning in Singapore.
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Objectives: Methicillin-resistant Staphylococcus aureus (MRSA) complicated skin 
and soft-tissue infection (cSSTI) is an infection associated with high health expendi-
ture for the Portuguese National Health Service (NHS). A decision analytic model 
